在没有头痛的情况下患有偏头痛光环的患者中使用levcromakalim的影响:一项实验性研究
Andreas Vinther Thomsen1,2, Mohammad Al-Mahdi Al-Karagholi1,2, Anders Hougaard2,3
1Danish Headache Center, Department of Neurology, Rigshospitalet - Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Glostrup, Denmark.
Cephalalgia : an international journal of headache
|August 20, 2024
概括
在大多数参与者中,Levcromakalim在没有头痛的情况下引发了偏头痛发作. 然而,它没有诱导光环,这表明trigeminovascular系统可能参与levcromakalimlim.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 众所周知,Levcromakalim可在易感个体中引发偏头痛与光环.
- 这项研究调查了levcromakalim在患有偏头痛,但没有头痛的患者中诱导偏头痛的潜力.
研究的目的:
- 评估levcromakalim在没有头痛的情况下经历偏头痛光环的个体中诱导偏头痛的作用.
主要方法:
- 这是一项双盲,随机,安慰剂控制,交叉研究,涉及8名成年参与者.
- 参与者接受了levcromakalim和盐水的静脉注射.
- 在输液后24小时内评估头痛,光环和相关症状.
主要成果:
- 在使用levcromakalim后,62.5%的参与者出现了偏头痛发作,而安慰剂后的37.5%.
- 没有参与者经历了levcromakalim管理后的光环.
- 主要终点,偏头痛类发作的发生,与levcromakalim.com更频繁地满足.
结论:
- 莱夫克罗马卡利姆 (Levcromakalim) 诱发光环的效果可能不是来自于直接的皮质扩散抑郁.
- 研究结果表明,trigeminovascular系统可能参与levcromakalim引发偏头痛的作用.
- 进一步的研究是有必要的,以探索Trigeminovascular系统的作用.
相关概念视频
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
275
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
275
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
238
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
238
01:19Antiasthma Drugs: Leukotriene Modifiers
260
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
260
01:26Cholinergic Antagonists: Therapeutic Uses
732
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
732